The Life Sciences Virtual Investor Forum, co-hosted by B2i Digital, Inc. and Zacks Small-Cap Research, will take place on June 24 and 25, 2026, providing investors with direct access to management teams from 22 public life sciences companies. The event, a B2i Digital Featured Conference, will be held virtually and includes live presentations, real-time Q&A, and one-on-one meetings.
B2i Digital serves as the Official Marketing Partner, leveraging its distribution and media engine to drive qualified investors to the forum. The company amplifies the event across its platform, reaching a proprietary network of more than 1.7 million retail and institutional market participants. B2i Digital has served as the marketing partner for over 115 investor conferences, operating under the motto "From Marketing to Meetings."
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, co-hosts the forum and brings its team of life sciences analysts to support the event. The company prepares independent research and related content for distribution across investor and media channels.
According to David Shapiro, Chief Executive Officer of B2i Digital, "Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides. Over two days, investors can meet companies across biotech, diagnostics, devices, and digital health, and reach their own conclusions."
The lineup includes companies from a wide range of sectors: clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Presenting companies on Day One (June 24) include Protalix BioTherapeutics, MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. Day Two (June 25) features Prostatype Genomics AB, Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
Each company will have 30 minutes for a live presentation followed by a Q&A session. Investors can request one-on-one meetings with management through the VIC site at this link. Replays will be available on B2i Digital and OTC Markets YouTube channels. Registration and company profiles are available at the Virtual Investor Conferences website.
Virtual Investor Conferences, an OTC Markets Group property, features public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets, throughout the year. This forum provides an interactive platform for companies to meet directly with investors online, offering efficient access to a broad audience.
The event highlights the growing importance of virtual access in the life sciences investment landscape, enabling investors to engage with multiple companies across diverse sub-sectors without the constraints of physical travel. For the industry, such forums facilitate capital formation and visibility for innovative therapies and technologies, potentially accelerating development and market adoption. Investors benefit from direct interactions with management, allowing for deeper due diligence and informed decision-making.
